Sheehan Disability Scale (SDS)

$4.00

PREVIEW ONLY, NOT A LICENSE FOR USE

Purchasing a download of the SDS on this website is NOT a license agreement for use. Click here to download the license agreement.

Dr. Sheehan licenses the SDS in paper format for distribution as follows : 1) in paper format for any uses; or 2) in fixed pdf form, paper form, or both for use in clinical or academic research trials or studies.

There is a charge per individual use (not per patient enrolled). The amount must be paid in full before study initiation.


Dr. Sheehan can design customized additional optional modules for the MINI / MINI Kid for other disorders and can customize scales to meet the needs of a specific study or clinical setting. Contact Dr. Sheehan at davidVsheehan@gmail.com to discuss a customized version designed for your needs.

Dr. Sheehan only provides consultation, guidance on regulatory agency questions, and training to those who license the MINI / MINI Kid or scales directly from him. Contact Dr. Sheehan at davidVsheehan@gmail.com for additional information.


For information about virtual web-based training on the SDS – which include a video, a quiz, and a certificate of completion of training – email training@harmresearch.org:

  1. Adult Standard SDS Training

For certain sites, Dr. Sheehan can do an additional live Zoom question and answer session to address issues encountered after the raters at the site have done a dozen or so with real patients.

Please contact: davidVsheehan@gmail.com

Training video subtitles are available in multiple languages on request. Contact training@harmresearch.org for more information.


The non-profit Mapi Research Trust (MAPI) / ICON Language Services, in Lyon, France, is the sole translation service for existing non-English translations for all rating scales and diagnostic interviews that Dr. Sheehan licenses and distributes directly under a license from him.

Dr. Sheehan has collaborated closely with MAPI on these translations for over 15 years and continues to do so. This is to ensure the production of consistent and conceptually equivalent translations of the MINI and its variants and of Dr. Sheehan’s scales, and to be able to provide linguistic validation and certification of these translations. MAPI / Icon Language Services does not distribute the English source language version of the MINI / MINI Kid and scales, which are available from Dr. Sheehan directly.

When Dr. Sheehan fully executes your license agreement request, he will provide you with the information to contact MAPI / Icon Language Services to obtain consistent and conceptually equivalent, and linguistically validated translations and the related certificates.

MAPI / Icon Language Services may charge its own usual fees for this work.


The SDS has been cited over 3,000 times in publications.

Use the following citations in referencing the SDS:

  1. Sheehan KH; Sheehan DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. International Clinical Psychopharmacology 2008;23(2):70-83. DOI: http://dx.doi.org/10.1097/YIC.0b013e3282f2b4d6
  2. Sheehan DV, Harnett-Sheehan K, Raj BA (1996). The measurement of disability. Int Clin Psychopharmacol 11 (Suppl 3):89–95. PDF: http://journals.lww.com/intclinpsychopharm/Abstract/1996/06003/The_measurement_of_disability.15.aspx
  3. Leon AC, Shear MK, Portera L, et al: Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 27:78–82, 1992. DOI: http://dx.doi.org/10.1007/BF00788510
  4. Leon AC, Olfson M, Portera L, et al: Assessing impairment in primary care: a psychometric analysis of the Sheehan Disability Scale. Int J Psychiatry Med 27:93–105, 1997. DOI: http://dx.doi.org/10.2190/T8EM-C8YH-373N-1UWD
  5. Olfson M, Kathol RG, Weissman MM, Sheehan DV, Leon AC, Hoven C. Mental Disorders and Disability in a Primary Care Group Practice.  American Journal of Psychiatry.  1997; 154: 1734-1740. DOI: http://dx.doi.org/10.1176/ajp.154.12.1734
  6. Sheehan DV, Harnett-Sheehan K. Psychometric Assessment of Anxiety Disorders. Chapter 8 in Anxiety:  Psychobiological and Clinical Perspectives (Sartorius N, Andreoli V, Cassano G, Eisenberg L, Kielholz P, Pancheri P, & Racagni G, eds.  Hemisphere Publishing Corporation, Washington, DC.  1990; 85-100. ISBN: 1560320648, 9781560320647.
  7. Sheehan, D. V. (2000). Sheehan disability scale. Handbook of psychiatric measures, 113-115.  ISBN: 0890424152, 9780890424155.
  8. Sheehan DV, Meyers AL, Prakash A, Robinson MJ, Swindle RW, Russell JM, et al. The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. Current Medical Research and Opinion. 2008; 24(9):2457-66. DOI: http://dx.doi.org/10.1185/03007990802293643
  9. Sheehan, DV, Harnett-Sheehan, K, Spann, M, Thompson, H, Prakash, A. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. International clinical psychopharmacology. 2011;2: 75-83. DOI: http://dx.doi.org/10.1097/YIC.0b013e328341bb5f
  10. Sheehan DV, Chokka PR, Granger RE, Walton RJ, Raskin J, Sagman D. Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine. Human Psychopharmacology: Clinical and Experimental. 2011;26(3):242-51. DOI: http://dx.doi.org/10.1002/hup.1199
  11. Mancini, M, Sheehan DV, Demyttenaere, K, Amore, M, Deberdt, W, Quail, D, Sagman, D. Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies. International Clinical Psychopharmacology. 2012; 27(6): 298-309. DOI: http://dx.doi.org/10.1097/YIC.0b013e3283589a3f
  12. Sheehan DV, Locklear J, Svedsäter H, Datto C. Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate. International Clinical Psychopharmacology. 2012;27(5):239-48. DOI: http://dx.doi.org/10.1097/YIC.0b013e328356ac78
  13. Sheehan, DV, Svedsäter, H, Locklear, JC, Eriksson. Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): Data from a randomized-withdrawal, placebo-controlled maintenance study. Journal of Affective Disorders. 2013; 151(3): 906-913. DOI: http://dx.doi.org/10.1016/j.jad.2013.07.037

 

We use cookies to enhance your experience on the site and for customers to complete orders.